Answers are grounded in this paper and cite their sources.
Executive summary• The high prevalence and recurrence of pressure injuries (PIs) require new treatment strategies.• The goals of PI treatment and research should be holistic, encompassing quality of life, symptom control, patient-directed goals of care and survival, as well as cure.• Cellular, acellular and matrix-like products (CAMPs) are advanced wound-care tools that promote innate healing processes, such as stimulating fibroblast activity, granulation tissue formation and keratinocyte migration.• CAMPs have been shown to be safe and effective in full-thickness PIs and other hard-to-heal wounds.• Indications for CAMPs should include early application in complex wounds, multiple comorbidities or impaired healing capacity, with or without exposed deep structures.• Patient selection should consider absolute and relative contraindications for CAMPs, as well as differential diagnoses for PIs, such as skin failure and malignant or atypical wounds.• Patients treated with CAMPs require optimisation of offloading, mobility and tissue perfusion, along with addressing nicotine use and polypharmacy, as well as skin protection, nutrition and psychosocial support.• Application of CAMPs must be preceded by wound-bed preparation encompassing tissue debridement, inflammation/infection control, moisture management and optimisation of patient and social factors.• CAMPs should be applied in a clean environment following instructions for use, potentially supported by negative pressure wound therapy.• Use of CAMPs requires ongoing documentation and re-assessment of treatment efficacy and quality of life, with onward referral for osteomyelitis, fistulas or other arterial disease.• CAMPs use should be based in multidisciplinary collaboration and supported by patient and professional education.• The appropriate use of CAMPs in PIs should be applied across all payors and relevant sites of service.• Research on CAMPs in PIs should make wider use of real-world data to support the limited number and narrow scope of randomised control trials.
No takes yet. Share an insight, caveat, or question.
Desvigne et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: